Jan Wehkamp1, Martin Götz, Klaus Herrlinger, Wolfgang Steurer, Eduard F Stange. 1. Department of Internal Medicine I - Gastroenterology, Hepatology, Infectiology, University Hospital of Tübingen, Asklepios Klinik Nord - Heidberg, Hamburg, Department of Internal Medicine I (Gastroenterology, Hepatology and Endocrinology), Robert-Bosch-Krankenhaus, Stuttgart.
Abstract
BACKGROUND: Inflammatory bowel diseases are common in Europe, with prevalences as high as 1 in 198 persons (ulcerative colitis) and 1 in 310 persons (Crohn's disease). METHODS: This review is based on pertinent articles retrieved by a search in PubMed and in German and European guidelines and Cochrane reviews of controlled trials. RESULTS: Typically, the main clinical features of inflammatory bowel diseases are diarrhea, abdominal pain, and, in the case of ulcerative colitis, peranal bleeding. These diseases are due to a complex immunological disturbance with both genetic and environmental causes. A defective mucosal barrier against commensal bowel flora plays a major role in their pathogenesis. The diagnosis is based on laboratory testing, ultrasonography, imaging studies, and, above all, gastrointestinal endoscopy. Most patients with Crohn's disease respond to budesonide or systemic steroids; aminosalicylates are less effective. Refractory exacerbations may be treated with antibodies against tumor necrosis factor (TNF) or, more recently, antibodies against integrin, a protein of the cell membrane. In ulcerative colitis, aminosalicylates are given first; if necessary, steroids or antibodies against TNF-α or integrin are added. Maintenance therapy to prevent further relapses often involves immunosuppression with thiopurines and/or antibodies. Once all conservative treatment options have been exhausted, surgery may be necessary. CONCLUSION: The treatment of chronic inflammatory bowel diseases requires individually designed therapeutic strategies and the close interdisciplinary collaboration of internists and surgeons.
BACKGROUND:Inflammatory bowel diseases are common in Europe, with prevalences as high as 1 in 198 persons (ulcerative colitis) and 1 in 310 persons (Crohn's disease). METHODS: This review is based on pertinent articles retrieved by a search in PubMed and in German and European guidelines and Cochrane reviews of controlled trials. RESULTS: Typically, the main clinical features of inflammatory bowel diseases are diarrhea, abdominal pain, and, in the case of ulcerative colitis, peranal bleeding. These diseases are due to a complex immunological disturbance with both genetic and environmental causes. A defective mucosal barrier against commensal bowel flora plays a major role in their pathogenesis. The diagnosis is based on laboratory testing, ultrasonography, imaging studies, and, above all, gastrointestinal endoscopy. Most patients with Crohn's disease respond to budesonide or systemic steroids; aminosalicylates are less effective. Refractory exacerbations may be treated with antibodies against tumor necrosis factor (TNF) or, more recently, antibodies against integrin, a protein of the cell membrane. In ulcerative colitis, aminosalicylates are given first; if necessary, steroids or antibodies against TNF-α or integrin are added. Maintenance therapy to prevent further relapses often involves immunosuppression with thiopurines and/or antibodies. Once all conservative treatment options have been exhausted, surgery may be necessary. CONCLUSION: The treatment of chronic inflammatory bowel diseases requires individually designed therapeutic strategies and the close interdisciplinary collaboration of internists and surgeons.
Authors: A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis Journal: J Crohns Colitis Date: 2010-01-15 Impact factor: 9.071
Authors: A Dignass; J C Preiss; D E Aust; F Autschbach; A Ballauff; G Barretton; B Bokemeyer; S Fichtner-Feigl; S Hagel; K R Herrlinger; G Jantschek; A Kroesen; W Kruis; T Kucharzik; J Langhorst; M Reinshagen; G Rogler; D Schleiermacher; C Schmidt; S Schreiber; H Schulze; E Stange; M Zeitz; J C Hoffmann; A Stallmach Journal: Z Gastroenterol Date: 2011-08-24 Impact factor: 2.000
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: David Laharie; Arnaud Bourreille; Julien Branche; Matthieu Allez; Yoram Bouhnik; Jerome Filippi; Frank Zerbib; Guillaume Savoye; Maria Nachury; Jacques Moreau; Jean-Charles Delchier; Jacques Cosnes; Elena Ricart; Olivier Dewit; Antonio Lopez-Sanroman; Jean-Louis Dupas; Franck Carbonnel; Gilles Bommelaer; Benoit Coffin; Xavier Roblin; Gert Van Assche; Maria Esteve; Martti Färkkilä; Javier P Gisbert; Philippe Marteau; Stephane Nahon; Martine de Vos; Denis Franchimont; Jean-Yves Mary; Jean-Frederic Colombel; Marc Lémann Journal: Lancet Date: 2012-10-10 Impact factor: 79.321
Authors: Jolanda M van Dieren; Ad A van Bodegraven; Ernst J Kuipers; Eke N Bakker; Alexander C Poen; Herman van Dekken; Edward E S Nieuwenhuis; C Janneke van der Woude Journal: Inflamm Bowel Dis Date: 2009-02 Impact factor: 5.325
Authors: Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts Journal: Gastroenterology Date: 2014-02 Impact factor: 22.682
Authors: Darline Garibay; Karolina E Zaborska; Michael Shanahan; Qiaonan Zheng; Katie M Kelly; David C Montrose; Andrew J Dannenberg; Andrew D Miller; Praveen Sethupathy; Bethany P Cummings Journal: Obes Surg Date: 2019-05 Impact factor: 4.129
Authors: Jan Wehkamp; Martin Götz; Klaus Herrlinger; Wolfgang Steurer; Eduard F Stange Journal: Dtsch Arztebl Int Date: 2016-07-01 Impact factor: 5.594
Authors: Simon U Jaeger; Thomas Klag; Katharina Hoeger; Siegfried Klumpp; Markus Escher; Nisar Malek; Eduard Stange; Jan Wehkamp Journal: Inflamm Intest Dis Date: 2018-11-09